Mid Europa Partners (MEP), a private equity fund, announced the sale of Walmark, one of the leading producers of dietary supplements in Central and Eastern Europe. The purchaser is Stada, but the transaction has yet to be approved by the antitrust authorities.
Finalisation of the transaction in 2020
The Walmark acquisition is part of Stada’s strategy. The company wants to become a market leader in two pillars: generic products and over-the-counter branded products. Walmark will increase the position of Stada in the countries of Central and Eastern Europe, but the company will also look for new markets for the products of the Czech manufacturer.
The value of the transaction was not disclosed. The parties expect that it will be finalised in the first quarter of 2020, after obtaining the consent of antitrust authorities. Walmark has been in the portfolio of Mid Europa Partners since December 2012, when the fund bought a 50% stake. In February 2016. MEP increased its stake in the company to 100% following the purchase of shares from the Walach family.
Walmark: almost 30 years on the market
Walmark was established in 1990. It is a Czech company with a focus on Central and Eastern Europe. It operates primarily in Slovakia, Poland, Bulgaria, Romania, Hungary and the Baltic Republics (Lithuania, Latvia, Estonia).
It also exports products to approximately 40 countries, including the Middle East, South-East Asia, Central Asia and the Balkan countries. In total, the company has 950 products in its portfolio, which are available in 49 markets.
The leading products of the company in Poland are Omega 3-6-9, Sinulan, Pneumolan and Urinal.